NASDAQ · FTRE
Healthcare · Biotechnology
$22.49
Down-$0.26 (-1.12%)
Updated Oct 19, 2026, 8:04 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · FTRE
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
FTRE closed at $22.49 after 20 trading sessions, up 12.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $23.04 | $23.135 | $21.86 | $22.49 | 1.9M |
| Oct 15, 2026 | $21.93 | $23.07 | $21.63 | $22.745 | 2.91M |
| Oct 14, 2026 | $20.45 | $22.15 | $20.25 | $21.34 | 2.94M |
| Oct 13, 2026 | $21.11 | $21.215 | $20.60 | $20.92 | 767.67K |
| Oct 12, 2026 | $20.84 | $21.3118 | $20.675 | $21.00 | 1.24M |
| Oct 9, 2026 | $20.37 | $21.005 | $20.16 | $20.84 | 931.31K |
| Oct 8, 2026 | $20.14 | $20.455 | $19.78 | $20.37 | 1.96M |
| Oct 7, 2026 | $20.38 | $21.11 | $20.24 | $20.56 | 2.25M |
| Oct 6, 2026 | $21.99 | $23.51 | $20.73 | $20.78 | 2.65M |
| Oct 5, 2026 | $20.00 | $21.20 | $19.855 | $21.11 | 2.27M |
| Oct 2, 2026 | $19.58 | $20.05 | $19.09 | $20.00 | 1.19M |
| Oct 1, 2026 | $19.88 | $19.96 | $19.05 | $19.40 | 1.94M |
| Sep 30, 2026 | $19.41 | $20.02 | $19.39 | $19.95 | 1.48M |
| Sep 29, 2026 | $19.89 | $20.39 | $19.42 | $19.74 | 1.17M |
| Sep 28, 2026 | $19.54 | $20.97 | $19.35 | $20.06 | 1.62M |
| Sep 25, 2026 | $19.90 | $20.285 | $19.35 | $19.89 | 708.91K |
| Sep 24, 2026 | $19.40 | $20.49 | $19.25 | $20.02 | 1.23M |
| Sep 23, 2026 | $20.25 | $20.71 | $19.50 | $19.52 | 1.07M |
| Sep 22, 2026 | $20.13 | $20.575 | $20.13 | $20.43 | 1.51M |
| Sep 21, 2026 | $20.29 | $20.44 | $19.665 | $20.02 | 1.05M |
The latest Smart Investors Daily articles mentioning FTRE.
Company
Market Activity
Research & News
FTRE research
Company profile and research snapshot.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | Deutsche Bank | Buy | — |
| Oct 6, 2026 | Barclays | Overweight | — |
| Sep 30, 2026 | UBS | Neutral | — |
| Aug 4, 2026 | TD Cowen | Buy | — |
| Jul 31, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 6, 2026
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 3.3% in the pre-market session after Barclays upgraded the company to Overweight from Equal Weight with a $38 price target.
Benzinga · Oct 6, 2026
Barclays analyst Luke Sergott upgrades Fortrea Holdings (NASDAQ:FTRE) from Equal-Weight to Overweight and raises the price target from $22 to $23.
Yahoo · Oct 5, 2026
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.
Yahoo · Oct 5, 2026
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will recei
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FTRE.
